CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance is a research paper published in Cancer Cell (2023). On theSindex it has a DataRank of 0. It has been cited 104 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: 5 P50 CA070907
National Cancer Institute
Grant: CA016672
National Cancer Institute
Grant: 1R01CA190628
National Cancer Institute
Grant: 1R01CA234183-01A1
National Cancer Institute
Grant: 1R01CA240257
National Cancer Institute
Grant: 1R01CA247975
National Cancer Institute
Grant: 1R50CA265307
Cancer Prevention and Research Institute of Texas
Grant: RP120348
Cancer Prevention and Research Institute of Texas
Grant: RP170002
NCI NIH HHS
Grant: R01 CA234183
NCI NIH HHS
Grant: P50 CA070907
NCI NIH HHS
Grant: R01 CA190628
NCI NIH HHS
Grant: R01 CA240257
NCI NIH HHS
Grant: R01 CA247975
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: R50 CA265307
National Institutes of Health
Emerson Collective
FWCI
23.64
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts